About us
Headquartered in Singapore, BioSyngen Group is dedicated in the clinical and commercial transfer of innovative immune-cell therapy technologies and products in Asia and China. The Group has closely research collaborations with world-renowned research institutions, jointly develop innovative technologies and products, receives world exclusive licenses of technologies and products. BioSyngen has a comprehensive and resourceful technical platform to support the development of cell therapy products, such as pre-clinical research, supplies of clinical grade virus vectors and mRNA, gamma-delta allogeneic cells, development of companion diagnostics, as well as T cell GMP production and clinical trial management. Founders of Biosyngen Group has jointly founded biotech companies such as Lion TCR, SCG Cell Therapy, BioCheetah.

On its Board of Scientific Advisors are internationally renowned scientists and collaborators, such as 2011 Nobel Laureate Professor Jules Alphonse Hoffman, Research Director CNRS Emeritus at CNRS Professor Jean-Paul Thiery, and Fellow of the Royal Society Professor Sir David Lane. Founded in 2016, through synergistically integrating its resources and network, BioSyngen has efficiently transformed cell therapy and diagnostic projects into clinical development stage. The Group strives to become the leader in biotechnology transfer of innovative immune cell therapy in Asia and China. Currently, BioSyngen conducts clinical trial projects in Singapore, Australia and China.
Board of Scientific Advisors Board of Directors
Examples of Biotech Transformation


In July 2015, Dr. Victor Li and Prof. Antonio Bertoletti co-founded Lion TCR Pte. Ltd. in Singapore, the company received the global exclusive in-license from The Agency for Science, Technology and Research(A*STAR) of Singapore, focusing on the development of TCR-T cell therapy for liver cancer, preliminary results in clinical trials have shown the effectiveness of therapy.


​Dr. Victor Li of Biosyngen Group founded SCG Cell Therapy Pte. Ltd. together with Prof. Ulrike Protzer from Institute of Virology, The Technical University of Munich (TUM). In July 2018, the company successively obtained the exclusive in-license of Class I and Class II T Cell receptor (TCR) patents related to TCR-T Cell Therapy.

Join Us

● Opportunity to work with world renowned institutes, with leading scientists that develop innovative technologies and products to solve unmet clinical needs
● Development of innovative Immune cell therapy with emphasis on quality and efficiency and clinical validation of innovative technologies
● Partnering and sharing success with Employees

"We value every employee."
——Dr. Victor Li, Founder of Biosyngen Group

  • Singapore Headquarter
    71 Ayer Rajah Crescent #04-21 Singapore 139951
  • Guangzhou, China
    Room 720,7F, No.2 Ascendas 1st Street, China-Singapore Guangzhou Knowledge City, Guangzhou, Guangdong Province, 510555, People's Republic of China
  • Dalian, China
    Lvshunkou District, Dalian City, Liaoning Province
    (Coming Soon)